Nowa wersja platformy jest już dostępna.
Przejdź na


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2009 | 4 | 1 | 32-36
Tytuł artykułu

Coronary artery atherosclerosis in patients with the initial and the early stage of chronic renal failure

Treść / Zawartość
Warianty tytułu
Języki publikacji
The recent clinical data indicate that the initial and the early stages of chronic renal failure (CRF) may lead to increased incidence of cardiovascular complications and increased extent of coronary artery disease (CAD). This retrospective study was aimed to determine the effects of coexisting diabetes mellitus type 2 (DM-2) and the extent of atherosclerosis in coronary vessels in patients with mildly reduced kidney function (glomerular filtration rate GFR = 89–60 ml/min) and moderately reduced kidney function (GFR = 59–30 ml/min). The study patients included 53 subjects with creatinine concentration above 120 μmol/l as a cut-off level for the initial stage and compensated CRF. The distributions of coronary artery stenosis were also analysed with respect to DM-2 coexistence and levels of haemoglobin glikolised (HbA1c). The odds ratio of pathological changes in coronary arteries in patients with GFR = 44–30 ml/min, with respect to the number of affected vessels - only one, more than one or more than two - were 7.22, 4.90 and 3.55, respectively. In CRF patients with GFR = 60–89 ml/min the odds ratio of one, more than one and more than two vessels with stenosis and CAD was 1.93, 1.70 and 1.53, respectively. DM-2 was not related to the risk of significant coronary artery stenosis and did not enhance the pre-existing changes in the study setting. Our results demonstrate that the initial and the early stages of CRF were significant risk factors for coronary stenoses and for enhancing the pre-existing changes.

Opis fizyczny
  • Department of Nephrology, Hypertension and Family Medicine, Medical University, 90-549, Lodz, Poland
  • Department of Nephrology, Hypertension and Family Medicine, Medical University, 90-549, Lodz, Poland
  • [1] Foley R.N., Parfrey P.S., Sarnak M.J., Clinical epidemiology of cardiovascular disease in chronic renal disease, Am. J. Kidney Dis., 1998, 32, S112–S119[Crossref]
  • [2] Levin A, Foley R.N., Cardiovascular disease in chronic renal insufficiency, Am. J. Kidney Dis., 2000, 36, S24–S30[Crossref]
  • [3] Collins A.J., Cardiovascular mortality in end-stage renal disease, Am. J. Med. Sci., 2003, 325, 163–167[Crossref]
  • [4] Levey A.S., Eknoyam G., Cardiovascular disease in chronic renal disease, Nephrol. Dial. Transplant., 1999, 14, 828–833[Crossref]
  • [5] Harnett J.D., Foley R.N., Kent G.M., Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors, Kidney Int., 1995, 47, 884–890[Crossref]
  • [6] Sarnak M.J., Levey A.S., Schoolwerth A.C., Kidney disease as a risk factor for development of cardiovascular disease. A statement from the AHA councils on kidney in cardiovascular disease. High Blood Pressure Research, Clinical cardiology and epidemiology and prevention, Circulation, 1993, 108, 2154–2169[Crossref]
  • [7] Al-Ahmad A., Sarnak M.J., Salem D.N., Konstam M.A., Cause and management of heart failure in patients with chronic renal disease, Semin. Nephrol., 2001, 21, 3–12[Crossref]
  • [8] Horl W.H., Atherosclerosis and uremic retention solutes, Nephrology Forum, Kidney Int., 2004, 66, 1719–1731[Crossref]
  • [9] Sorensen C.R., Brendorp B., Rask-Madsen C., The prognostic importance of creatinine clearance after acute myocardial infarction, Eur. Heart J., 2002, 23, 948–952[Crossref]
  • [10] Tokmakova M.P., Skali H., Kenchaiah S., Chronic kidney disease, cardiovascular risk and response to angiotensin-converting enzyme inhibition after myocardial infarction: The Survival and Ventricular Enlargement (SAVE) study, Circulation, 2004, 110, 3667–3673[Crossref]
  • [11] Anavekar N.S., McMurray J.J.V., Velazquez E.J., Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction, N. Engl. J. Med., 2004, 351, 1285–1295[Crossref]
  • [12] Amann K., Tyralla K., Cardiovascular changes in chronic renal failure - pathogenesis and therapy, Clinical Nephrol., 2002, 58, S62–S72
  • [13] Dries D.L., Exner D.V., Domanski M.J., The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction, J. Am. Coll. Cardiol., 2000, 35, 681–689[Crossref]
  • [14] Go A.S., Chertow G.M., Fan D., Chronic kidney disease and the risks of death, cardiovascular events and hospitalisation, N. Engl. J. Med., 2004, 351, 1296–1305[Crossref]
  • [15] Munter P., He J., Hamm L., Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States, J. Am. Soc. Nephrol., 2002, 13, 745–753
  • [16] Rysz J., Banach M., Stolarek R.A., Pasnik J., Cialkowska-Rysz A., Koktysz R., et al., Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy, J. Nephrol., 2007., 20, 444–52
  • [17] Selcoki Y., Turgut F., Kanbay M., Ozkara A., Tekin O., Uz B., et al., Cardiac valve calcifications and predictive parameters in hemodialysis patients, Cent. Eur. J. Med., 2007, 2, 304–31[Crossref][WoS]
  • [18] Rysz J., Błaszczak R., Banach M., Kedziora-Kornatowska K., Kornatowski T., Tański W., et al., Evaluation of selected parameters of the antioxidative system in patients with type 2 diabetes in different periods of metabolic compensation, Arch. Immunol. Ther. Exp., 2007, 55, 335–40[WoS][Crossref]
  • [19] Bachórzewska-Gajewska H., Małyszko J., Sitniewska E., Małyszko J., Dobrzycki S., Prevention of contrast-induced nephropathy in patients undergoing percutaneous coronary interventions in everyday clinical practice, Arch. Med. Sci., 2006, 2, 256–261
  • [20] Rysz J., Kocur E., Blaszczak R., Bartnicki P., Stolarek R.A., Piechota M., IL-2, IL-6 and IL-8 levels remain unaltered in the course of immunosuppressive therapy after renal transplantation, Cent. Eur. J. Med., 2008, 3, 199–202[WoS][Crossref]
Typ dokumentu
Identyfikator YADDA
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.